RTX stock slips ahead of earnings as Airbus flags Pratt & Whitney engine bottlenecks

RTX stock slips ahead of earnings as Airbus flags Pratt & Whitney engine bottlenecks

New York, Jan 26, 2026, 21:28 EST — Market closed.

  • RTX shares dipped 0.9% on Monday as investors awaited results set for release before Tuesday’s open.
  • Airbus flagged persistent delivery issues linked to Pratt & Whitney engines.
  • Options traders are betting on about a 5% move after earnings.

RTX (RTX.N) shares dipped 0.9% to end Monday at $194.13, as investors braced for the aerospace and defense giant’s quarterly earnings report set to drop before the market opens. 1

The update arrives amid mounting pressure from Airbus, a key Pratt & Whitney customer. Airbus CEO Guillaume Faury highlighted that the planemaker’s “most serious difficulties” lie with Pratt & Whitney engines and rival CFM, intensifying concerns about supply reliability ahead of RTX’s earnings. 2

This is key since Pratt & Whitney’s delivery speed and repair volume directly impact cash flow timing and customer payouts, while RTX aims to keep up the pace at its defense unit, Raytheon. Investors often react more to guidance than the actual quarterly results, searching for clues that backlog is converting into revenue.

RTX plans to report its fourth-quarter and full-year 2025 earnings on Tuesday before U.S. markets open, with a conference call set for 8:30 a.m. ET. 3

Wall Street is looking for earnings near $1.47 per share on roughly $22.7 billion in revenue, based on consensus estimates released Monday. 4

Signals in the commercial aviation supply chain remain mixed. Embraer’s commercial chief, Arjan Meijer, told Reuters that Pratt & Whitney has “largely overcome shortages and maintenance bottlenecks,” but added the dispute over geared turbofan engines on Airbus jets has intensified. 5

The geared turbofan, or GTF, stands as Pratt & Whitney’s flagship narrowbody engine line and remains a focal point for investors due to accelerated inspection demands. RTX had earlier projected it would pull 600 to 700 engines from Airbus A320neo-family planes for extensive checks between 2023 and 2026, linked to a powder-metal problem. 6

RTX slipped Monday, mirroring losses across major aerospace and defense stocks like Lockheed Martin and Boeing. 7

Options trading points to a big move in RTX following Tuesday’s earnings, with implied volatility pricing in about a 5% swing. This is a market measure of how much the stock could jump or drop after the report. 8

But the situation is double-edged. Should RTX signal inspection and compensation costs exceeding expectations, or if engine deliveries and shop visits lag behind customer hopes, the stock might still take a hit despite beating top-line estimates.

Investors are zeroing in on Tuesday’s earnings and, crucially, RTX’s outlook on 2026 cash flow, Pratt & Whitney engine availability, and the speed of the GTF inspection program during the 8:30 a.m. ET call.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Intuitive Surgical stock in focus after FDA clears da Vinci 5 for heart procedures
Previous Story

Intuitive Surgical stock in focus after FDA clears da Vinci 5 for heart procedures

Bloom Energy stock drops as Jefferies lifts target but stays bearish ahead of Feb. 5 results
Next Story

Bloom Energy stock drops as Jefferies lifts target but stays bearish ahead of Feb. 5 results

Go toTop